American Journal of Clinical Dermatology

, Volume 13, Issue 1, pp 64–65 | Cite as

KIT and BRAF Mutational Status in a Patient with a Synchronous Lentigo Maligna Melanoma and a Gastrointestinal Stromal Tumor

  • Rubeta N. Matin
  • David Gonzalez
  • Lisa Thompson
  • Sally R. Lambert
  • Farrah Bakr
  • Nathalie Dhomen
  • Richard Marais
  • Jane M. McGregor
  • Peter Szlosarek
  • Rino Cerio
  • Catherine A. Harwood
Case Letter

Notes

Acknowledgments

RNM is supported by the Medical Research Council Clinical Training Fellowship, UK. CAH is supported by Cancer Research UK. The authors have no conflicts of interest to declare.

References

  1. 1.
    Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24 (26): 4340–6PubMedCrossRefGoogle Scholar
  2. 2.
    Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106 (9): 2005–11PubMedCrossRefGoogle Scholar
  3. 3.
    Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14 (23): 7726–32PubMedCrossRefGoogle Scholar
  4. 4.
    Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23 (12): 2735–43PubMedCrossRefGoogle Scholar
  5. 5.
    Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14 (21): 6821–8PubMedCrossRefGoogle Scholar
  6. 6.
    Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009; 22 (11): 1446–56PubMedCrossRefGoogle Scholar
  7. 7.
    Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121 (2): 257–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Rubeta N. Matin
    • 1
  • David Gonzalez
    • 2
  • Lisa Thompson
    • 2
  • Sally R. Lambert
    • 1
  • Farrah Bakr
    • 1
  • Nathalie Dhomen
    • 3
  • Richard Marais
    • 3
  • Jane M. McGregor
    • 1
  • Peter Szlosarek
    • 4
  • Rino Cerio
    • 5
  • Catherine A. Harwood
    • 1
  1. 1.Centre for Cutaneous Research, Blizard InstituteBarts and The London School of Medicine and DentistryLondonUK
  2. 2.Section of Haemato-OncologyThe Institute of Cancer ResearchSuttonUK
  3. 3.Section of Cell and Molecular Biology, The Institute of Cancer ResearchChester Beatty LaboratoriesLondonUK
  4. 4.Barts Cancer InstituteQueen Mary University of LondonLondonUK
  5. 5.ICMS Pathology Group, Barts and The London School of Medicine and DentistryInstitute of PathologyLondonUK

Personalised recommendations